MARKET

VIRI

VIRI

Virios Therapeutics Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

7.69
+0.60
+8.45%
Closed 19:56 08/11 EDT
OPEN
7.28
PREV CLOSE
7.09
HIGH
7.95
LOW
7.19
VOLUME
112.54K
TURNOVER
--
52 WEEK HIGH
7.95
52 WEEK LOW
3.300
MARKET CAP
64.06M
P/E (TTM)
-3.7985
1D
5D
1M
3M
1Y
5Y
Virios Therapeutics GAAP EPS of -$0.44 beats by $0.07
Virios Therapeutics press release (<span class=...
Seekingalpha · 21h ago
BRIEF-Virios Therapeutics reports Q2 results
BRIEF-Virios Therapeutics reports Q2 results
Reuters · 21h ago
Virios Therapeutics, Inc. to Present at Investor Summit Group’s Q3 Virtual Conference
ATLANTA, August 10, 2022--Virios Therapeutics, Inc. (Nasdaq: VIRI), a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debilitating chronic diseases, including fibromyalgia, today announced that G...
Business Wire · 1d ago
Virios Therapeutics: The 'Virus Hypothesis' That Stands to Change the Lives of 10M Americans
Company's September Phase 2b trial results could be transformative for fibromyalgia patients New York, New York--(Newsfile Corp. - August 8, 2022) - PCG Digital -- Life may change for the better for the 10 million Americans suffering from fibromyalgia. The...
Newsfile · 3d ago
Virios Therapeutics to Report Second Quarter 2022 Financial Results and Provide Corporate Update on Thursday, August 11, 2022
ATLANTA, August 04, 2022--Virios Therapeutics, Inc. (Nasdaq: VIRI), a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debilitating chronic diseases, including fibromyalgia, announced today that i...
Business Wire · 08/04 11:05
Virios Therapeutics (Nasdaq: VIRI) Advancing Potential Paradigm Shift in Fibromyalgia Treatment
Armed with near-term catalyst, VIRI is poised for next growth stage New York, New York--(Newsfile Corp. - July 26, 2022) - PCG Digital -- Development-stage biotechnology company Virios Therapeutics (NASDAQ: VIRI) is working to advance a new therapeutic app...
Newsfile · 07/26 12:30
Virios' Promising Fibromyalgia Treatment Candidate Expects September 2022 Phase 2b Results
New York, New York--(Newsfile Corp. - July 19, 2022) - PCG Digital -- With the aim of improving the standard of care for the 10 million Americans living with fibromyalgia ("FM"), Virios Therapeutics (NASDAQ: VIRI) anticipates Phase 2b results for its lead ...
Newsfile · 07/19 12:30
12 Health Care Stocks Moving In Friday's Pre-Market Session
 
Benzinga · 07/15 12:14
More
No Data
Learn about the latest financial forecast of VIRI. Analyze the recent business situations of Virios Therapeutics Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

0.00%Strong Buy
100.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average VIRI stock price target is 17.00 with a high estimate of 22.00 and a low estimate of 12.00.
High22.00
Average17.00
Low12.00
Current 7.69
EPS
Actual
Estimate
-0.55-0.41-0.28-0.14
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Q3 2022
Institutional Holdings
Institutions: 15
Institutional Holdings: 1.10M
% Owned: 13.15%
Shares Outstanding: 8.33M
TypeInstitutionsShares
Increased
6
125.26K
New
2
22.10K
Decreased
3
1.14K
Sold Out
2
193
  • Performance
  • Asset Allocation
  • Dividend History
No Data
No Data
No Data
No Data
About VIRI
Virios Therapeutics, Inc., formerly Virios Therapeutics, LLC., is a development-stage biotechnology company focused on advancing antiviral therapies to treat diseases associated with a viral triggered abnormal immune response, such as fibromyalgia (FM). Its lead development candidate is IMC-1, which is a fixed dose combination of famciclovir and celecoxib. IMC-1 represents a combination antiviral therapy designed to synergistically suppress Herpes Simplex Virus-1 (HSV-1) activation and replication. Its HSV-1 root cause of chronic illnesses such as FM, irritable bowel disease (IBS), chronic fatigue syndrome and functional somatic syndrome. The Company is developing its initial candidate, IMC-1, for people who are suffering from fibromyalgia.

Webull offers kinds of Virios Therapeutics Inc stock information, including NASDAQ:VIRI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VIRI stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading VIRI stock methods without spending real money on the virtual paper trading platform.